# TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms

> **NCT03503968** · PHASE1,PHASE2 · TERMINATED · sponsor: **Medigene AG** · enrollment: 9 (actual)

## Conditions studied

- Safety
- Tolerability
- Feasibility
- Treatment Efficacy

## Interventions

- **DRUG:** MDG1011
- **OTHER:** Investigator Choice therapy

## Key facts

- **NCT ID:** NCT03503968
- **Lead sponsor:** Medigene AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-27
- **Primary completion:** 2022-06-28
- **Final completion:** 2022-07-15
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** The clinical trial is terminated after the completion of phase I without moving to Phase II.
- **Last updated:** 2023-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03503968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03503968, "TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03503968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*